DXA estimates BMD by comparing how bone attenuates two low-dose X-ray beams. The paired signals provide an estimate of the mineral contained within bone tissue rather than relying on a single X-ray measurement. This result helps assess skeletal strength and supports evaluation of possible bone fragility.
T-scores and Z-scores are commonly used to interpret DXA-derived BMD values. They help place an individual measurement into a clinical assessment of bone status, including recognition of low bone mass or osteoporosis. Their interpretation gives clinicians a standardized way to connect the measurement with diagnostic and management decisions.
Following BMD over time shows whether skeletal measurements change during treatment or with aging. This longitudinal information adds context to a single assessment and can help clinicians evaluate ongoing skeletal health. Tracking these changes supports decisions about continued prevention, diagnosis, or management of bone fragility.
A DXA assessment produces BMD values that can be interpreted with T-scores or Z-scores. Together, these outputs help identify low bone mass and osteoporosis and provide information relevant to estimating fracture risk. The results therefore connect the imaging measurement with clinically meaningful assessment of skeletal health.
Clinicians use BMD testing to help identify low bone mass and osteoporosis, estimate fracture risk, and support decisions about prevention and management of bone fragility. Testing also has value when skeletal measurements need to be monitored during treatment or as aging produces changes in bone status.
In medical research, BMD measurements provide a way to study skeletal health alongside fracture outcomes. Researchers can examine how bone measurements relate to fragility and how they change with treatment or aging. This context helps connect quantitative assessment of bone tissue with broader questions about prevention, diagnosis, and clinical management.